These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 37949237)

  • 1. Escitalopram population pharmacokinetics and remedial strategies based on CYP2C19 phenotype.
    Liu X; Ju G; Huang X; Yang W; Chen L; Li C; He Q; Xu N; Zhu X; Ouyang D
    J Affect Disord; 2024 Feb; 346():64-74. PubMed ID: 37949237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Escitalopram Personalized Dosing: A Population Pharmacokinetics Repository Method.
    Liu X; Ju G; Yang W; Chen L; Xu N; He Q; Zhu X; Ouyang D
    Drug Des Devel Ther; 2023; 17():2955-2967. PubMed ID: 37789969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Escitalopram and Sertraline Population Pharmacokinetic Analysis in Pediatric Patients.
    Poweleit EA; Taylor ZL; Mizuno T; Vaughn SE; Desta Z; Strawn JR; Ramsey LB
    Clin Pharmacokinet; 2023 Nov; 62(11):1621-1637. PubMed ID: 37755681
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2C19-Guided Escitalopram and Sertraline Dosing in Pediatric Patients: A Pharmacokinetic Modeling Study.
    Strawn JR; Poweleit EA; Ramsey LB
    J Child Adolesc Psychopharmacol; 2019 Jun; 29(5):340-347. PubMed ID: 30817183
    [No Abstract]   [Full Text] [Related]  

  • 5. Population pharmacokinetics model for escitalopram in Chinese psychiatric patients: effect of CYP2C19 and age.
    Liu S; Xiao T; Huang S; Li X; Kong W; Yang Y; Zhang Z; Ni X; Lu H; Zhang M; Shang D; Wen Y
    Front Pharmacol; 2022; 13():964758. PubMed ID: 35924062
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of age, weight, and CYP2C19 genotype on escitalopram exposure.
    Jin Y; Pollock BG; Frank E; Cassano GB; Rucci P; Müller DJ; Kennedy JL; Forgione RN; Kirshner M; Kepple G; Fagiolini A; Kupfer DJ; Bies RR
    J Clin Pharmacol; 2010 Jan; 50(1):62-72. PubMed ID: 19841156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Escitalopram Metabolic Ratios as Potential Biomarkers for Predicting CYP2C19 Poor Metabolizers.
    Faraj P; Hermansen A; Molden E; Hole K
    Ther Drug Monit; 2022 Dec; 44(6):720-728. PubMed ID: 36372933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cytochrome P450 2C19 polymorphisms on citalopram/escitalopram exposure: a systematic review and meta-analysis.
    Chang M; Tybring G; Dahl ML; Lindh JD
    Clin Pharmacokinet; 2014 Sep; 53(9):801-11. PubMed ID: 25154506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
    Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
    Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.
    Takahashi T; Mohamud MA; Smith AR; Jacobson PA; Jaber MM; Alharbi AF; Fisher J; Kirstein MN
    Antimicrob Agents Chemother; 2021 Aug; 65(9):e0062321. PubMed ID: 34097481
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetic-pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study.
    Jung YS; Jin BH; Park MS; Kim CO; Chae D
    CPT Pharmacometrics Syst Pharmacol; 2024 Jan; 13(1):29-40. PubMed ID: 37775990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
    Kumar Y; Kung S; Shinozaki G
    J Psychopharmacol; 2014 Dec; 28(12):1143-8. PubMed ID: 25122046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remedial dosing recommendations for delayed or missed doses of valproic acid in patients with epilepsy based on Monte Carlo simulations.
    Wang CY; Jiao Z; Ding JJ; Yu EQ; Zhu GX
    Epilepsy Behav; 2020 Oct; 111():107265. PubMed ID: 32640410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of CYP2C19 Genotype on Escitalopram Exposure and Therapeutic Failure: A Retrospective Study Based on 2,087 Patients.
    Jukić MM; Haslemo T; Molden E; Ingelman-Sundberg M
    Am J Psychiatry; 2018 May; 175(5):463-470. PubMed ID: 29325448
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Remedial dosing recommendations for delayed or missed doses of lamotrigine in pediatric patients with epilepsy using Monte Carlo simulations.
    Yu EQ; Jiao Z; Wang CY; Ding JJ; Zhang XH
    Epilepsy Behav; 2019 Jul; 96():132-140. PubMed ID: 31132614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.
    Bishop JR; Najjar F; Rubin LH; Guter SJ; Owley T; Mosconi MW; Jacob S; Cook EH
    Pharmacogenet Genomics; 2015 Nov; 25(11):548-54. PubMed ID: 26313485
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escitalopram population pharmacokinetics in people living with human immunodeficiency virus and in the psychiatric population: Drug-drug interactions and probability of target attainment.
    Courlet P; Guidi M; Glatard A; Alves Saldanha S; Cavassini M; Buclin T; Marzolini C; Eap CB; Decosterd LA; Csajka C;
    Br J Clin Pharmacol; 2019 Sep; 85(9):2022-2032. PubMed ID: 31144347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CYP2C19 Genotyping May Provide a Better Treatment Strategy when Administering Escitalopram in Chinese Population.
    Huang X; Li C; Li C; Li Z; Li X; Liao J; Rao T; Chen L; Gao L; Ouyang D
    Front Pharmacol; 2021; 12():730461. PubMed ID: 34512354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
    Waade RB; Hermann M; Moe HL; Molden E
    Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Semi-mechanistic population pharmacokinetics analysis reveals distinct CYP2C19 dependency in the bioactivation of vicagrel and clopidogrel to active metabolite M15-2.
    Zhang L; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li YG; He Y; Zhang EY; Yan X
    Eur J Pharm Sci; 2022 Oct; 177():106264. PubMed ID: 35868434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.